Membrane-wrapped Nanoparticles for Nucleic Acid Delivery

Overview

Journal Biomater Sci

Publisher Royal Society of Chemistry

Specialties Biomedical Engineering
Pharmacology

Date 2022 Jul 7

PMID 35796319

Authors

Mackenzie A Scully

Eric H Sterin

Emily S Day

Affiliations

Soon will be listed here.

Abstract

There is an unmet need for carriers that can deliver nucleic acids (NAs) to cancer cells and tumors to perpetuate gene regulation and manage disease progression. Membrane-wrapped nanoparticles (NPs) can be loaded with exogenously designed nucleic acid cargoes, such as plasmid deoxyribonucleic acid (pDNA), messenger ribonucleic acid (mRNA), small interfering RNA (siRNA), microRNA (miRNA), and immunostimulatory CpG oligodeoxynucleotides (CpG ODNs), to mitigate challenges presented by NAs' undesirable negative charge, hydrophilicity, and relatively large size. By conjugating or encapsulating NAs within membrane-wrapped NPs, various physiological barriers can be overcome so that NAs experience increased blood circulation half-lives and enhanced accumulation in intended sites. This review discusses the status of membrane-wrapped NPs as NA delivery vehicles and their advancement in gene regulation for cancer management and . With continued development, membrane-wrapped NPs have great potential as future clinical tools to treat cancer and other diseases with a known genetic basis.

Citing Articles

Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.

ACYP2 functions as an innovative nano-therapeutic target to impede the progression of hepatocellular carcinoma by inhibiting the activity of TERT and the KCNN4/ERK pathway.

Wu Y, Bao H, Wu J, Chen B, Xu J, Jin K J Nanobiotechnology. 2024; 22(1):557.

PMID: 39267048 PMC: 11391695. DOI: 10.1186/s12951-024-02827-4.

Effects of Synthetic Toll-Like Receptor 9 Ligand Molecules on Pulpal Immunomodulatory Response and Repair after Injuries.

Quispe-Salcedo A, Yamazaki T, Ohshima H Biomolecules. 2024; 14(8).

PMID: 39199319 PMC: 11353191. DOI: 10.3390/biom14080931.

Membrane-Cloaked Nanoparticles for RNA Interference of β-Catenin in Triple-Negative Breast Cancer.

Scully M, Wilhelm R, Wilkins D, Day E ACS Biomater Sci Eng. 2024; 10(3):1355-1363.

PMID: 38306303 PMC: 10939768. DOI: 10.1021/acsbiomaterials.4c00160.

Combination cancer imaging and phototherapy mediated by membrane-wrapped nanoparticles.

Aboeleneen S, Scully M, Kramarenko G, Day E Int J Hyperthermia. 2023; 40(1):2272066.

PMID: 37903544 PMC: 10698846. DOI: 10.1080/02656736.2023.2272066.

References

Kotin R . Large-scale recombinant adeno-associated virus production. Hum Mol Genet. 2011; 20(R1):R2-6. PMC: 3095058. DOI: 10.1093/hmg/ddr141. View

Chandler M, Brittany Johnson M, Panigaj M, Afonin K . Innate immune responses triggered by nucleic acids inspire the design of immunomodulatory nucleic acid nanoparticles (NANPs). Curr Opin Biotechnol. 2019; 63:8-15. PMC: 7246180. DOI: 10.1016/j.copbio.2019.10.011. View

Li J, Ai Y, Wang L, Bu P, Sharkey C, Wu Q . Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials. 2015; 76:52-65. PMC: 4662903. DOI: 10.1016/j.biomaterials.2015.10.046. View

Johnson D, Zhou J, Kroll A, Fang R, Yan M, Xiao C . Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2021; 36(4):994-1005. PMC: 8979812. DOI: 10.1038/s41375-021-01432-w. View

Manthorpe M, Hartikka J, Felgner J, Rundell A, Margalith M, Dwarki V . Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther. 1993; 4(4):419-31. DOI: 10.1089/hum.1993.4.4-419. View

Han S, Lee Y, Lee M . Biomimetic cell membrane-coated DNA nanoparticles for gene delivery to glioblastoma. J Control Release. 2021; 338:22-32. DOI: 10.1016/j.jconrel.2021.08.021. View

Harris J, Scully M, Day E . Cancer Cell Membrane-Coated Nanoparticles for Cancer Management. Cancers (Basel). 2019; 11(12). PMC: 6966582. DOI: 10.3390/cancers11121836. View

Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes J . Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer. 2010; 9:154. PMC: 2911446. DOI: 10.1186/1476-4598-9-154. View

Kroll A, Fang R, Jiang Y, Zhou J, Wei X, Yu C . Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. Adv Mater. 2017; 29(47). PMC: 5794340. DOI: 10.1002/adma.201703969. View

10.

Vaughan H, Green J, Tzeng S . Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery. Adv Mater. 2019; 32(13):e1901081. PMC: 6923623. DOI: 10.1002/adma.201901081. View

11.

Kim H, Kim A, Miyata K, Kataoka K . Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev. 2016; 104:61-77. DOI: 10.1016/j.addr.2016.06.011. View

12.

Vijayan V, Uthaman S, Park I . Cell Membrane-Camouflaged Nanoparticles: A Promising Biomimetic Strategy for Cancer Theragnostics. Polymers (Basel). 2019; 10(9). PMC: 6404000. DOI: 10.3390/polym10090983. View

13.

Chen H, Deng J, Yao X, He Y, Li H, Jian Z . Bone-targeted erythrocyte-cancer hybrid membrane-camouflaged nanoparticles for enhancing photothermal and hypoxia-activated chemotherapy of bone invasion by OSCC. J Nanobiotechnology. 2021; 19(1):342. PMC: 8549398. DOI: 10.1186/s12951-021-01088-9. View

14.

Sun H, Su J, Meng Q, Yin Q, Chen L, Gu W . Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors. Adv Mater. 2016; 28(43):9581-9588. DOI: 10.1002/adma.201602173. View

15.

Long Y, Wu X, Li Z, Fan J, Hu X, Liu B . PEGylated WS nanodrug system with erythrocyte membrane coating for chemo/photothermal therapy of cervical cancer. Biomater Sci. 2020; 8(18):5088-5105. DOI: 10.1039/d0bm00972e. View

16.

Chen J, Wu Z, Ding W, Xiao C, Zhang Y, Gao S . SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer. Theranostics. 2020; 10(4):1619-1632. PMC: 6993241. DOI: 10.7150/thno.40489. View

17.

Sun T, Zhang Y, Pang B, Hyun D, Yang M, Xia Y . Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(46):12320-64. DOI: 10.1002/anie.201403036. View

18.

Mashel T, Tarakanchikova Y, Muslimov A, Zyuzin M, Timin A, Lepik K . Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods. Biomaterials. 2020; 258:120282. DOI: 10.1016/j.biomaterials.2020.120282. View

19.

Xiong J, Wu M, Chen J, Liu Y, Chen Y, Fan G . Cancer-Erythrocyte Hybrid Membrane-Camouflaged Magnetic Nanoparticles with Enhanced Photothermal-Immunotherapy for Ovarian Cancer. ACS Nano. 2021; 15(12):19756-19770. DOI: 10.1021/acsnano.1c07180. View

20.

Liao Y, Zhang Y, Blum N, Lin J, Huang P . Biomimetic hybrid membrane-based nanoplatforms: synthesis, properties and biomedical applications. Nanoscale Horiz. 2020; 5(9):1293-1302. DOI: 10.1039/d0nh00267d. View